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plications were derived from the DCCT, Framingham, and
WESDR studies. Clinical input was taken from the 26-week mul-
ticenter, multinational, open-label trial. Costs were retrieved
from published sources. Direct and indirect costs of diabetes
complications and treatment with IDet/IAsp or IGlar/IAsp were
projected over patients’ lifetimes from a societal health care per-
spective. Costs and outcomes were discounted at 3.5% annually.
RESULTS: In this analysis, a reduction in major hypoglycemic
events associated with IDet/IAsp led to an increase in quality-
adjusted life expectancy of 0.11 quality-adjusted life years
(QALYs). Direct lifetime costs were slightly higher with
IDet/IAsp treatment than with IGlar/IAsp treatment, leading to
ICURs of €21,455 per QALY gained in Austria and €13,607 per
QALY gained in Germany. When indirect costs were included 
in the analysis, IDet/IAsp was dominant to IGlar/IAsp in both
countries. CONCLUSIONS: IDet/IAsp therapy was associated
with improved quality-adjusted life expectancy, leading to an
ICUR based on direct costs that was well within the range 
considered to represent good value for money in Austria and
Germany.
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OBJECTIVES: Forty percent of hypertensive type-2 diabetes
patients will develop nephropathy, indicating end organ damage,
increased risk of cardiovascular disease (CVD), and death. In the
US, screening rates and nephropathy treatment are suboptimal.
We assessed the health economic impact of nephropathy screen-
ing followed by optimal antihypertensive therapy in those who
have nephropathy in the US. METHODS: A Markov/Monte
Carlo model simulated lifetime impacts of screening for
nephropathy using semi-quantitative urine dipsticks in a primary
care setting, and subsequent addition of irbesartan 300mg to
conventional antihypertensives in hypertensive type-2 diabetes
patients in those patients identiﬁed as having nephropathy. Pro-
gression from no renal disease to end-stage renal disease (ESRD)
was simulated. Probabilities, utilities and costs of CVD events,
medications and ESRD treatment came from published sources.
Number of days of ESRD avoided, quality-adjusted life years
(QALYs) and direct costs were projected. Second-order Monte
Carlo simulation was used to account for uncertainty in multi-
ple parameters. Costs and QALYs were discounted three percent
annually. RESULTS: Screening followed by optimized treatment
led to 36,683 ± 5767 days of ESRD avoided in 1000 simulated
patients, with incremental costs per QALY gained of $7315.
There was a 98% probability that screening and optimized anti-
hypertensive therapy would be considered cost-effective with a
willingness to pay ≥$20,000. Sensitivity analysis showed that
screening and optimized treatment would dominate “no screen-
ing” in patients <55 years of age. CONCLUSIONS: In hyper-
tensive patients with type-2 diabetes, screening for albuminuria
followed by optimal antihypertensive treatment is cost-effective
in a US setting.
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INTRODUCTION: Diabetes increases resource use, and com-
plications add to costs. The purpose of this study was to char-
acterise the association between increasing frequency and
severity of the symptoms of diabetic peripheral neuropathy
(SDPN), measured by the Neuropathy Total Symptom Score
(NTSS)-6-SA, and health care resource use and loss of produc-
tivity. METHODS: A postal survey was mailed to subjects iden-
tiﬁed at random from hospital records as having either type-1 or
Type-2 diabetes using the same methods as the Health Outcomes
Data Repository (HODaR). Cross-sectional, univariate and mul-
tivariate analyses were used to test for the associations in this
preliminary analysis of the ﬁrst 604 responses. Where appropri-
ate, four categories were used for cross-sectional analysis based
on quartiles of the NTSS-6-SA scores, Q1 being the lowest score.
RESULTS: The mean age of respondents was 64 years (IQR
55–73); 58% male and the mean duration of diabetes were 14
years (IQR 5–18). 24% reported no SDPN symptoms. The mean
number of days in hospital in the previous year was: Q1 = 3.4
and Q4 = 8.3. Mean number of ambulatory care in last year: Q1
= 4.4 and Q4 = 10.6. Mean contacts with a GP or nurse in the
community over six months: Q1 = 6.0 and Q4 = 14.3. Mean
productive days lost in the previous six months: Q1 = 35 and
Q4 = 128 (note: multiple categories can occur on the same day).
In multivariate analysis adjusting for age and other complica-
tions, the NTSS-6-SA score remained highly signiﬁcant. Using
days in hospital since 1995 (10 years) as the dependent variable,
there was an increase of 0.3 days per NTSS-6-SA unit (p <
0.001), and using outpatient attendances since 1997 as the
dependent variable (8 years), there was an increase of 1.13 visits
per unit (p < 0.001). CONCLUSIONS: There was a direct asso-
ciation between increase SDPN and increasing health care
resource use; furthermore, increasing SDPN was associated with
lost productivity.
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Diabetes Mellitus is a signiﬁcant public health problem in the
United States. Monitoring of glycmeic status, eye exam, LDL-C
levels, and nephropathy testing is essential for diabetes care.
OBJECTIVES: To improve diabetic care within a Medicaid
Managed Care Organization. METHODS: This is a prospective
interventional, pre- and post comparison study with retrospec-
tive claims data and medical chart review. Four indicators:
HbA1c, LDL-C, eye exam, and nephropathy monitoring were
targeted for quality improvement interventions. A random
sample of 411 diabetic members aged 18–75 years was selected
using administrative and medical records. Patient demographics,
past medical history, eye exam, and laboratory data were
recorded using a standard form. Patient and provider interven-
tions included: case manager phone outreach program to remind
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members to follow up with their physicians; patient reminder
postcards; educational materials and newsletters; Diabetic
Control Network—a 12-month patient self educated program;
vision provider contract requirement included performance guar-
antees to improve eye exam rates; mailings to providers a list of
their diabetic patients who had not received the necessary ser-
vices; provider and patient gift certiﬁcate incentive programs;
providers on site education, and updated ADA diabetes stan-
dards of care. Results of baseline measurement and 12-month
post intervention re-measurement were compared. RESULTS: A
signiﬁcant improvement in all selected quality indicators were
found: HbA1c poorly controlled rate was 48.42%, a decreased
of 19.46% (p < 0.001) from baseline; eye exam rates was
48.66%, an increased of 10.70% (p < 0.05) from baseline; LDL-
C level <130mg/dL was 55.96%, an increased of 10.46% (p <
0.05) from baseline, LDL-C level <100mg/dL was 31.87%; and
nephropathy monitoring was 53.28%, an increased of 8.51% (p
< 0.05) from baseline. CONCLUSIONS: Results of this study
demonstrated substantial improvement in all selected diabetes
indicators. Although results of our interventions are encourag-
ing, expanded effort is still needed to further improve rates of
diabetic management among Medicaid members.
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The high prevalence of undiagnosed diabetes and the large pro-
portion of individuals with complications at diagnosis (50%
according to UKPDS 33) argue for screening for Type-2 diabetes.
The NHANES study conﬁrms the substantially higher risk of
death, lower survival, and lower life expectancy of diabetic
adults compared with non-diabetic adults. A UK Prospective
Diabetes Study shows that intensive blood-glucose control can
reduce risk of any diabetes-related death and any diabetes-
related endpoints. OBJECTIVE: The aim of the study was to
assess cost-effectiveness of active screening for DM and intensive
blood-glucose control in comparison with conventional treat-
ment in patients with DM II in the Polish population.
METHODS: The Markov model of DM progression to stimu-
late lifetime and related health care cost was constructed. Demo-
graphic characteristics of a stimulated cohort as well as cost of
health care were based on a CODIP study population. Costs
were analysed from a societal viewpoint and included only direct
medical costs. Costs of active searching for DM and the distrib-
ution of people on diagnostic pathways came from an epidemi-
ological Screen-Pol 2 study. The age-dependant risk of death and
transition probabilities between disease stages were obtained
from the NHANES study. The effectiveness of active blood-
glucose control was derived from the UKPDS 33. RESULTS: In
the long term (20 years), a strategy based on active blood-glucose
control could bring an additional 0.4 life years saved (LYS) per
patient. An additional LYS costs €457. If active blood-glucose
control is preceded by the active screening for DM, this strategy
could bring 0.71 LYS per patient. The cost-effectiveness ratio
amounts to €10,863/LYS. CONCLUSIONS: The most effective
strategy in DM management is based on an early detection
program and active blood-glucose control. The cost-effectiveness
ratio for active glucose control is extremely low.
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OBJECTIVE: Use of acetyl salicylic acid (ASA) for primary pre-
vention (PP) and secondary prevention (SP) of cardiovascular
disease (CVD) in adult diabetic patients is highly recommended.
This study was conducted in order to determine the use of ASA
and to assess the achievement of therapeutic targets in diabetic
patients. METHODS: This is a retrospective and observational
study. Sample consisted of patients >18 years with diabetes 
mellitus followed in four primary care centers. Measurements
included demographics, use of ASA and/or anticoagulant drugs,
co-morbidities, clinical parameters and proportion of patient at
therapeutic target (TT). Descriptive statistics, chi-square test and
logistic regression model were used for signiﬁcance. RESULTS:
A total of 4140 diabetic patients were analyzed, 79.1% 
(95% conﬁdence interval: 77.7%–80.5%) in PP and 20.9%
(18.2%–23.7%) in SP. Mean age was 64.1 (13.8) years, and
49.3% of patient were men (PP: 46.3; SP: 60.7; p = 0.000). ASA
were prescribed on a routine basis in 29.2% (27.8%–30.6%);
20.8% (19.4%–22.2%) in PP and 60.8% (57.6%–64.0%) in SP.
Proportion of patient at TT was 48.0% for hypertensives and
59.8% for hypercholesterolemics, being these the most frequent
antecedents observed in SP. Older patients [OR = 1.01
(1.00–1.02); p = 0.011], number of cardiovascular-risk factors
[OR = 1.14 (CI: 1.03–1.27); p = 0.013], LDL-c TT [OR = 1.42
(1.06–1.88); p = 0.017], and a poor metabolic control of gly-
cated hemoglobin [OR = 1.51 (1.22–1.89); p = 0.000] were
covariates associated to the use of ASS in PP. CONCLUSIONS:
Treatment with ASA is underused for PP in patients with dia-
betes mellitus in Primary Care. Achievement of TT should be
improved.
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OBJECTIVE: This study determined the predictors of antidia-
betes medication adherence and health care costs in adults with
Type-2 diabetes mellitus in the United States. METHODS: The
2000 Medical Expenditure Panel survey was used for the analy-
ses. The population for analyses was identiﬁed using ICD-9 CM
codes for Type-2 diabetes. The predictor variables were demo-
graphics variables, self-reported health status (EuroQol score),
and health services utilization variables. The dependent variables
in this analysis were diabetes medication possession (number of
diabetes medication reﬁlls) and annual health care costs. Multi-
variate weighted analysis was performed to identify signiﬁcant
predictors of medication utilization and health care costs.
RESULTS: There were 11.7 million patients with reported Type-
2 diabetes in the United States in 2000, based on survey extrap-
olation. On an average, there were ten diabetes drug reﬁlls
reported by patients. The average annual health care costs for
these patients were $7466, while the mean EuroQol summary
score was 48%. Increase in the health status summary score
(EuroQol) by 10% was associated with a slight (1%) decrease
in diabetes drug reﬁlls (p < 0.05). An additional diabetes related
emergency visit or an inpatient visit was associated with a nearly
50% increase compared to the average diabetes medication uti-
